Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies.
Fiche publication
Date publication
mai 2018
Journal
Clinical genitourinary cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel
Tous les auteurs :
Denouel A, Heutte N, Escudier B, Kurtz JE, Santos MD, Longato N, Desrues L, Dauchy S, Lange M, Sevin E, Rieux C, Clarisse B, Castel H, Noal S, Joly F
Lien Pubmed
Résumé
Targeted therapies, in particular antiangiogenic therapies (AATs), have become the standard of treatment for metastatic renal cell carcinoma (mRCC). Although common adverse effects like fatigue have been well-established, sexual disorders induced by these treatments, although often reported, have been poorly evaluated. The aim of this study was to evaluate the impact of AATs on the sexual life of patients with mRCC and the relationships with quality of life (QoL), fatigue, and biologic parameters.
Mots clés
Biologic parameters, Fatigue, Quality of life, Renal cancer, Sexual disorders
Référence
Clin Genitourin Cancer. 2018 May 21;: